[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Rohan S, Tu JJ, Kao J, Mukherjee P, Campagne F, Zhou XK, Hyjek E, Alonso MA, Chen YT: Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes. Clin Cancer Res; 2006 Dec 1;12(23):6937-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.
  • PURPOSE: To compare gene expression profiles of chromophobe renal cell carcinoma (RCC) and benign oncocytoma, aiming at identifying differentially expressed genes.
  • EXPERIMENTAL DESIGN: Nine cases each of chromophobe RCC and oncocytoma were analyzed by oligonucleotide microarray.
  • RESULTS: Unsupervised hierarchical clustering separated the chromophobe RCC and oncocytoma into two distinct groups.
  • By a combination of data analysis approaches, we identified 11 candidate genes showing consistent differential expression between chromophobe RCC and oncocytoma.
  • Five of these genes, AP1M2, MAL2, PROM2, PRSS8, and FLJ20171, were shown to effectively separate these two tumor groups by quantitative reverse transcription-PCR using fresh tissue samples, with similar trends seen on formalin-fixed tissues.
  • Immunohistochemical analysis revealed selective expression of MAL2 and claudin 8 in distal renal tubules, with MAL2 antibody showing differential expression between chromophobe RCC and oncocytoma.
  • Functional analyses suggest that genes encoding tight junction proteins and vesicular membrane trafficking proteins, normally expressed in distal nephrons, are retained in chromophobe RCC and lost or consistently down-regulated in oncocytoma, indicating that these two tumor types, believed to be both derived from distal tubules, are likely distinctive in their histogenesis.
  • CONCLUSIONS: We showed that chromophobe RCC and oncocytoma are distinguishable by mRNA expression profiles and a panel of gene products potentially useful as diagnostic markers were identified.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Gene Expression Profiling. Kidney Neoplasms / genetics. Membrane Proteins / genetics. Thyroid Neoplasms / genetics. Vesicular Transport Proteins / genetics

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • GeneTex Inc. NCBI Redirect Page | Genetex Inc. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145811.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / AP1M2 protein, human; 0 / Adaptor Protein Complex 1; 0 / Adaptor Protein Complex mu Subunits; 0 / FLJ20171 protein, human; 0 / MAL2 protein, human; 0 / Membrane Glycoproteins; 0 / Membrane Proteins; 0 / Myelin and Lymphocyte-Associated Proteolipid Proteins; 0 / PROM2 protein, human; 0 / Proteolipids; 0 / RNA, Messenger; 0 / RNA-Binding Proteins; 0 / Vesicular Transport Proteins; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / prostasin
  •  go-up   go-down


2. Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI: Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer; 2003 Mar 1;97(5):1186-94
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
  • BACKGROUND: Hürthle cell neoplasms, often considered a variant of follicular thyroid neoplasms, represent 3% of thyroid carcinomas.
  • Only a handful of publications have focused on the biologic behavior, prognostic factors, and treatment outcomes of Hürthle cell carcinoma.
  • The objective of the current study was to identify the clinical and pathologic features of Hürthle cell carcinomas that predict disease progression or death.
  • METHODS: The authors reviewed medical records of patients who were treated for Hürthle cell carcinoma (HCC) and Hürthle cell adenoma (HCA) at The University of Texas M. D.
  • RESULTS: The authors identified 127 patients with Hürthle cell neoplasms, 89 patients with HCC and 38 patients with HCA.
  • Forty percent of patients in the HCC group died of thyroid carcinoma, whereas no patients in the HCA group died of the disease.
  • There has been no improvement in all-cause and disease specific mortality in the past 5 decades for patients with these neoplasms.
  • Univariate analysis identified older age, higher disease stage, tumor size, extraglandular invasion, multifocality, lymph node disease, distant metastasis, extensive surgery, external beam radiation therapy, and chemotherapy as factors that were associated with decreased survival.
  • Although radioactive iodine treatment had no overall effect on survival, subgroup analysis showed that patients who received radioactive iodine for adjuvant ablation therapy had better outcomes compared either with patients who did not receive radioactive iodine or with patients who received radioactive iodine as treatment for residual disease.
  • The association of extensive surgery, external beam radiation therapy, and chemotherapy with worse survival also disappeared once those factors were analyzed together with other prognostic factors, such as distant metastases.
  • Radioactive iodine therapy may confer a survival benefit when it is used for adjuvant ablation therapy, but not when residual disease is present.
  • The authors could not demonstrate a survival benefit for the use of extensive surgery, external beam radiation therapy, or chemotherapy.
  • [MeSH-major] Adenoma, Oxyphilic / surgery. Thyroid Neoplasms / pathology. Thyroid Neoplasms / surgery
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Iodine Radioisotopes / therapeutic use. Male. Middle Aged. Mortality. Prognosis. Survival Analysis. Thyroidectomy

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.
  • (PMID = 12599224.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iodine Radioisotopes
  •  go-up   go-down


3. Dasanu CA, Alexandrescu DT: Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma. South Med J; 2008 Feb;101(2):196-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral perinephric diffuse large B-cell lymphoma and synchronous renal oncocytoma.
  • An elderly patient who presented with bilateral perinephric diffuse large B-cell lymphoma and concomitant oncocytoma of the same location is reported.
  • Because of the patient's other medical conditions, systemic chemotherapy was not deemed feasible.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Kidney Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364624.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Matyja G, Dziekan T, Dobrzycki W: [Rare neck tumors: diagnosis and treatment]. Otolaryngol Pol; 2000;54 Suppl 31:87-9
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare neck tumors: diagnosis and treatment].
  • Among them were: paraganglioma--3 cases, neurilemmoma--3 cases, actinomycosis--2 cases and 1 case of plasmocytoma, ganglioneuroma, oncocytoma, lipoma, toxoplasmosis and cystic tumour of salivary gland origin.
  • Beside surgery antibiotics, chemotherapy and RTG therapy were applied, depending on the kind of the tumour.
  • Satisfactory results were obtained (12/14 patients are alive, 1 after removal of oncocytoma died due to cardio-vascular cause).
  • [MeSH-major] Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10974852.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] POLAND
  •  go-up   go-down


5. Maiuri F, Gangemi M, Giamundo A, Mariniello G, Colella A, Vergara P, Del Basso De Caro ML: Intracranial extension of salivary gland tumors. Clin Neuropathol; 2010 Jan-Feb;29(1):9-13
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The aim of this report is to describe 3 cases of salivary gland tumors with intracranial extension associated to an extracerebral mass lesion, and to discuss the frequence, pathology and treatment of these very rare localizations.
  • The primary tumors were an adenocarcinoma and a malignant oncocytoma of the parotid gland and an adenoid cystic carcinoma of the submandibular gland.
  • Surgical treatment consisted in the seemingly complete removal of 2 tumors with middle fossa localization and partial removal of the cerebellopontine angle lesion.
  • Radiotherapy was administered in all 3 cases and chemotherapy in 2.
  • [MeSH-major] Adenoma, Oxyphilic / pathology. Brain Neoplasms / pathology. Carcinoma, Adenoid Cystic / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Brain / pathology. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040327.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Mete O, Asa SL: Aldosterone-producing adrenal cortical adenoma with oncocytic change and cytoplasmic eosinophilic globular inclusions. Endocr Pathol; 2009;20(3):182-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aldosterone-producing adrenal cortical adenoma with oncocytic change and cytoplasmic eosinophilic globular inclusions.
  • The laparoscopic left adrenalectomy specimen revealed an adrenal cortical adenoma composed of varying proportions of oncocytic and clear cells, predominantly showing central oncocytic change.
  • Ultrastructural study revealed that the inclusions originated in degenerating mitochondria, explaining their association with the oncocytic phenotype of the tumor.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Adenoma / pathology. Aldosterone / secretion. Inclusion Bodies / pathology
  • [MeSH-minor] Aged. Antihypertensive Agents / therapeutic use. Female. Humans. Hyperaldosteronism / etiology. Hypertension / drug therapy. Hypertension / etiology. Microscopy, Electron, Transmission

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1998 Jul;433(1):5-12 [9692819.001]
  • [Cites] Virchows Arch. 2008 Sep;453(3):301-6 [18688642.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):938-46 [16133362.001]
  • [Cites] Semin Diagn Pathol. 1999 May;16(2):82-90 [10452573.001]
  • [Cites] Ultrastruct Pathol. 2002 Jul-Aug;26(4):229-35 [12227948.001]
  • [Cites] Hepatogastroenterology. 2008 May-Jun;55(84):900-2 [18705293.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1817-8 [15900303.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):973-8 [12218215.001]
  • [Cites] Rhinology. 2007 Mar;45(1):89-92 [17432078.001]
  • [Cites] Cancer. 1970 Dec;26(6):1300-10 [5483659.001]
  • [Cites] J Clin Pathol. 2004 Mar;57(3):225-32 [14990587.001]
  • [Cites] Hum Pathol. 2009 Apr;40(4):478-83 [19144383.001]
  • [Cites] Arch Pathol Lab Med. 1983 Apr;107(4):178-82 [6299227.001]
  • [Cites] Pathol Annu. 1992;27 Pt 1:263-304 [1736246.001]
  • [Cites] Pathol Int. 1996 Apr;46(4):286-91 [8726853.001]
  • [Cites] Br J Cancer. 2005 May 23;92(10):1892-8 [15841082.001]
  • (PMID = 19462261.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 4964P6T9RB / Aldosterone
  •  go-up   go-down


7. Kuroda N, Guo L, Toi M, Naruse K, Miyazaki E, Hayashi Y, Yoshikawa C, Ashida S, Shuin T, Enzan H: Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma. Appl Immunohistochem Mol Morphol; 2001 Dec;9(4):315-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paxillin: application of immunohistochemistry to the diagnosis of chromophobe renal cell carcinoma and oncocytoma.
  • In this study, 91 renal tumors--65 conventional renal cell carcinomas (RCCs), 14 papillary RCCs, 6 chromophobe RCCs, 4 collecting duct carcinomas, 2 oncocytomas--were investigated for the immunohistochemical expression of paxillin.
  • In a normal kidney, paxillin was predominantly expressed in the cytoplasm of distal tubules, loops of Henle, collecting ducts, and vascular smooth muscle cells.
  • An immunoblot analysis confirmed the presence of paxillin in healthy kidney, chromophobe RCC, and oncocytoma.

  • Genetic Alliance. consumer health - Chromophobe Renal Cell Carcinoma.
  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11759057.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytoskeletal Proteins; 0 / Neoplasm Proteins; 0 / PXN protein, human; 0 / Paxillin; 0 / Phosphoproteins
  •  go-up   go-down


8. Pan CC, Chen PC, Ho DM: The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases. Histopathology; 2004 Nov;45(5):452-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnostic utility of MOC31, BerEP4, RCC marker and CD10 in the classification of renal cell carcinoma and renal oncocytoma: an immunohistochemical analysis of 328 cases.
  • AIMS: To demonstrate the diagnostic utility of MOC31, BerEP4, renal cell carcinoma marker (RCC Ma) and CD10 in the classification of RCC and renal oncocytoma, based upon a comprehensive immunohistochemical analysis.
  • METHODS AND RESULTS: Immunohistochemistry was performed on 328 samples consisting of 256 clear cell/conventional, 27 papillary, 28 chromophobe, five collecting duct, five unclassified RCCs and seven renal oncocytomas using antibodies MOC31, BerEP4 and antibodies against cytokeratins (KL-1, CAM5.2, 34betaE12, cytokeratin 7), RCC Ma, epithelial membrane antigen, E-cadherin, CD10, CD15 and vimentin.
  • MOC31 and BerEP4 chiefly labelled distal tubules of normal kidney while RCC Ma and CD10 labelled the proximal tubules.
  • Twenty-three chromophobe RCCs (82%) were reactive for MOC31, while only four clear cell RCCs and three papillary RCCs were positive for this marker.
  • Clear cell RCCs were characterized by a high positive rate for CD10 (82%) and a low positive rate for BerEP4 (27%).
  • The CD10+/BerEP4- profile and RCC Ma+/BerEP4+ profile achieve moderate sensitivity and good specificity for clear cell RCC and papillary RCC, respectively.
  • The non-reactivity for both MOC31 and CD10 is helpful in distinguishing renal oncocytoma from RCC.
  • [MeSH-major] Adenoma, Oxyphilic / diagnosis. Biomarkers, Tumor. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis. Mitogen-Activated Protein Kinases. Neprilysin

  • Genetic Alliance. consumer health - Oncocytoma renal.
  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15500648.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125; EC 2.7.11.22 / MOK protein, human; EC 2.7.11.24 / Mitogen-Activated Protein Kinases; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


9. Kauffman EC, Barocas DA, Chen YT, Yang XJ, Scherr DS, Tu JJ: Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes. J Urol; 2009 May;181(5):2305-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of KAI1 metastasis suppressor protein in renal cell tumor histological subtypes.
  • This problem is most notable for the chromophobe subtype of renal cell carcinoma, which can be histologically indistinguishable from oncocytoma with investigational molecular markers failing to provide reliable differentiation.
  • KAI1 is a metastasis suppressor gene whose expression correlates inversely with the metastatic potential of most solid tumor cancer types.
  • MATERIALS AND METHODS: Immunohistochemical staining for KAI1 protein was performed in 152 nephrectomy specimens, including 48 clear cell, 35 papillary and 31 chromophobe renal cell carcinoma samples, 28 oncocytomas and 10 tumor-free kidneys.
  • KAI1 mRNA levels were compared by quantitative reverse transcriptase-polymerase chain reaction in an additional 22 chromophobe renal cell carcinoma and oncocytoma samples.
  • RESULTS: In all 10 tumor-free kidneys KAI1 protein was detected exclusively in distal tubule cell membranes.
  • Of the tumor specimens KAI1 protein was absent in all papillary renal cell carcinoma specimens.
  • It was present in only 1 of 48 clear cell renal cell carcinomas (2%) and 2 of 28 oncocytomas (7%) but only at low levels.
  • In contrast, 27 of 31 chromophobe renal cell carcinoma specimens (87%) expressed KAI1 protein, most at moderate or high levels.
  • The diagnostic accuracy of KAI1 immunostaining for discerning chromophobe renal cell carcinoma from oncocytoma was 90% with similar results observed at the RNA level.
  • CONCLUSIONS: KAI1 is an accurate biomarker for chromophobe renal cell carcinoma that may aid in the diagnostic differentiation of chromophobe renal cell carcinoma from oncocytoma.
  • It remains to be determined whether KAI1 expression contributes to the low metastatic potential of chromophobe renal cell carcinoma.
  • [MeSH-major] Adenoma, Oxyphilic / genetics. Carcinoma, Renal Cell / genetics. Carcinoma, Renal Cell / pathology. Extracellular Matrix Proteins / metabolism. Kidney Neoplasms / genetics. Kidney Neoplasms / pathology. Nerve Tissue Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19303095.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Extracellular Matrix Proteins; 0 / KAL1 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


10. Toma V, Zuber C, Sata T, Komminoth P, Hailemariam S, Eble JN, Heitz PU, Roth J: Thomsen-Friedenreich glycotope is expressed in developing and normal kidney but not in renal neoplasms. Hum Pathol; 2000 Jun;31(6):647-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In developing kidney, the TF was restricted to the loop of Henle, distal tubules, and peripheral collecting ducts, whereas its sialylated form was detectable in all epithelial differentiations derived from the 2 embryonic anlagen, the metanephrogenic blastema being unreactive.
  • The TF was exclusively expressed in the luminal cell surface and hence was inaccessible to immune reactions.
  • Analysis of a spectrum of renal neoplasms failed to detect the TF, with the exception of occasional staining of tubules in nephroblastoma.
  • Moreover, the sialylated TF was only detectable in oncocytoma, chromophobe renal cell carcinoma, cystic nephroma, nephroblastoma, and nephroblastomatosis complex and occasionally in type 1 papillary renal cell carcinoma.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10872656.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Coloring Agents; 0 / Lectins; 0 / Plant Lectins; 0 / amaranthin protein, Amaranthus; 3554-90-3 / Thomsen-Friedenreich antigen; EC 3.2.2.22 / Ribosome Inactivating Proteins; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


11. Okoń K: Pathology of renal tumors in adults. Molecular biology, histopathological diagnosis and prognosis. Pol J Pathol; 2008;59(3):129-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Since the fifties, the incidence of renal cancers has been increasing, but at the some time the prognosis has been improving.
  • In particular, in the last years, several new treatment modalities have been introduced, relying on the understanding of renal cancer biology.
  • The identified etiological factors include smoking, increased body mass, dietary factors and chronic renal disease.
  • There are several renal tumor types differing in morphology, molecular genetics and biology.
  • Inactivation of the VHL gene leads to formation of the most frequent form in adults, namely clear cell carcinoma.
  • At least two types of papillary carcinomas exist, which have different morphology and prognosis.
  • The molecular biology of chromophobe carcinoma and oncocytoma is poorly understood.
  • Some renal tumors have been described or recognized only relatively recently; these newer entities include multilocular cystic clear cell carcinoma, spindle cell papillary mucinous carcinoma, tubulocystic carcinoma, renal epithelial and stromal tumor, epithelioid and oncocytic angiomyolipoma.
  • The improved prognosis in renal cancer depends on earlier detection, but also on refinement of therapeutic methods.
  • Renal carcinoma is notorious for its low sensitivity to chemotherapy and radiotherapy.
  • For several years, immunological treatment with IL-2 and INF-alpha was the only adjuvant therapy method.
  • However, recently several new drugs have been introduced; they act on tyrosine-kinase receptors, VEGF, c-Met or mTOR pathway.


12. Seveso M, Taverna G, Giusti G, Benetti A, Piccinelli A, Graziotti P: Nephron sparing surgery of parenchymal kidney tumours in solitary kidney. Arch Ital Urol Androl; 2007 Mar;79(1):12-6
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The aim of this study is to assess the therapeutic efficacy of nephron sparing surgery (NSS) in our experience applied to patients with either bilateral renal cancer or patients with cancer in a solitary functioning kidney, from an oncological viewpoint as well as renal function.
  • Twenty-seven presented absolute indications with disease in functionally or anatomically solitary kidney.
  • Final histology showed 17 patients with clear cell renal carcinoma, six papillary cell carcinomas, one chromophobe carcinoma, one oncocytoma and two angiomyolipomas.
  • Two patients present secondary tumours (lung and liver), whereas one patient is being treated with chemotherapy for colon cancer Twenty-two patients are disease-free.
  • None of the 10 patients discharged with creatinine levels >2 mg/dL, were submitted to dialytic therapy during follow-up.
  • None of the patients discharged with normal renal function developed kidney failure.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484397.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


13. Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC, Haitel A: CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest; 2009 Apr;39(4):304-10
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD98hc (SLC3A2), a novel marker in renal cell cancer.
  • BACKGROUND: In a variety of malignant diseases, molecular targeting represents a therapeutic option, whereby, when compared with chemotherapy, fewer side effects are thought to be expected.
  • Especially in renal cell cancer (RCC), tyrosine kinase-inhibitors have been established as useful and highly effective therapy.
  • However, tyrosine kinase-inhibitors currently approved for RCC treatment lack single molecule specificity and bear a variety of side effects of the gastro-intestinal tract, skin, heart and haematopoietic system.
  • Therefore, the identification of novel cell surface markers is sought, which might lead to novel diagnostic and therapeutic strategies in cancer.
  • MATERIAL AND METHODS: Paraffin-embedded RCCs from a well characterized tissue bank were immunohistochemically quantified for embryonic transmembrane antigen CD98hc (SLC3A2) expression and semi-quantitative analyses were correlated with subtype or grade of differentiation.
  • RESULTS: We found increased CD98hc expression in different types of malign RCCs, among them clear cell (cc)RCC, papillary (p)RCC and chromophobe (ch)RCC, but lack of expression in the benign renal oncocytoma.
  • Furthermore, the more malignant type II pRCC significantly higher expressed CD98hc than the less malignant and more differentiated type I pRCC (type II 83.34%, type I 4.76% CD98hc positive, P < 0.00001; n = 51).
  • The established marker for type I pRCC, Cytokreatin 7, showed 95.24% expression in type I and 26.67% expression in type II pRCC (P < 0.00001, n = 51).
  • In pRCCs, CD98hc might represent a novel and reliable marker for type II pRCC.
  • [MeSH-major] Antigens, CD98 Heavy Chain / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Renal Cell / diagnosis. Kidney Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Kidney cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19292886.001).
  • [ISSN] 1365-2362
  • [Journal-full-title] European journal of clinical investigation
  • [ISO-abbreviation] Eur. J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD98 Heavy Chain; 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Pennell NA, Daniels GH, Haddad RI, Ross DS, Evans T, Wirth LJ, Fidias PH, Temel JS, Gurubhagavatula S, Heist RS, Clark JR, Lynch TJ: A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid; 2008 Mar;18(3):317-23
Hazardous Substances Data Bank. THYROGLOBULIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologic subtypes included papillary (41%), follicular (22%), anaplastic (19%), medullary (15%), and Hürthle cell carcinomas (4%).
  • After 3, 6, and 12 months of treatment, 48%, 24%, and 12% of patients had stable disease (SD), respectively.
  • CONCLUSIONS: Although gefitinib therapy did not result in any tumor responses, 32% of patients had reductions in tumor volume that did not meet criteria for partial response rate.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / pathology. Quinazolines / administration & dosage. Thyroid Neoplasms / drug therapy. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / drug therapy. Adenocarcinoma, Follicular / pathology. Adenoma, Oxyphilic / drug therapy. Adenoma, Oxyphilic / pathology. Aged. Carcinoma, Medullary / drug therapy. Carcinoma, Medullary / pathology. Female. Humans. Kaplan-Meier Estimate. Male. Severity of Illness Index. Thyroglobulin / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Thyroid. 2008 Mar;18(3):279-80 [18341374.001]
  • (PMID = 17985985.001).
  • [ISSN] 1050-7256
  • [Journal-full-title] Thyroid : official journal of the American Thyroid Association
  • [ISO-abbreviation] Thyroid
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; 9010-34-8 / Thyroglobulin; S65743JHBS / gefitinib
  •  go-up   go-down


15. Cozzi DA, Schiavetti A, Morini F, Castello MA, Cozzi F: Nephron-sparing surgery for unilateral primary renal tumor in children. J Pediatr Surg; 2001 Feb;36(2):362-5
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Definition of the role of nephron-sparing surgery (NSS) in the treatment of children with primary unilateral renal tumor (URT).
  • Preoperative 2-drug chemotherapy was given to all patients more than 6 months of age.
  • Between 1992 and 1995, 3-drug chemotherapy was used after NSS.
  • Thereafter, following NSS, 2-drug chemotherapy was given if no microscopic residual disease was found on final histologic examination.
  • Seven children had standard histology nephroblastoma, 1 highly differentiated epithelial type nephroblastoma, 1 oncocytoma, and 1 cystic nephroma.
  • All children are alive and disease free with good functioning of the affected kidney after NSS, at a mean follow-up of 40.7 months (range, 2 to 100 months).
  • CONCLUSION: NSS should be considered in selected children with URT, especially in patients with increased risk for metachronous tumor or renal disease, and in patients with benign or low-grade malignant URT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11172435.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement